HU6
Asset
Controlled metabolic protonophore that uncouples oxidative phosphorylation to increase energy expenditure and reduce fat.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Not known
- 4
- Indications
- 2
- Trials
- 1
- Developer
Indications
4Fatty liver disease
Phase 2, Active not recruiting, NCT05979779, clinicaltrials.gov, Oct 31, 2026
Mash metabolic dysfunction associated steatohepatitis
Phase 2, Recruiting, NCT07491458, clinicaltrials.gov, Oct 31, 2026
Metabolic dysfunction-associated steatohepatitis
Phase 2, Active not recruiting, NCT05979779, clinicaltrials.gov, Oct 31, 2026
1 more
In the full profile
- Owner and partners1
- Trials2
- Competitors12
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.